drugset

drugset / Trial / NCT01692782

Adult Attention Deficit Hyperactivity Disorder

NCT01692782 ↗

Phase 2 Completed 341 enrolled Sumitomo Pharma America, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 2 study of SEP-225289 in adults with attention deficit hyperactivity disorder (ADHD).

Timeline

Start: 2012-12
Primary completion: 2013-11
Completion: 2013-12

Publications

Hopkins SC, Sunkaraneni S, Skende E, Hing J, Passarell JA, Loebel A, Koblan KS. Pharmacokinetics and Exposure-Response Relationships of Dasotraline in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults. Clin Drug Investig. 2016 Feb;36(2):137-46. doi: 10.1007/s40261-015-0358-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dasotraline	Small molecule	4 mg	Oral
Subject	Dasotraline	Small molecule	8 mg	Oral

Indications